| 52.28 1.23 (2.41%) | 05-08 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 61.88 | 1-year : | 72.27 |
| Resists | First : | 52.97 | Second : | 61.88 |
| Pivot price | 48.32 |
|||
| Supports | First : | 45.18 | Second : | 40.36 |
| MAs | MA(5) : | 51.68 |
MA(20) : | 47.29 |
| MA(100) : | 44.54  |
MA(250) : | 62.67 |
|
| MACD | MACD : | 2.9 |
Signal : | 2.6 |
| %K %D | K(14,3) : | 87.1 |
D(3) : | 87.5 |
| RSI | RSI(14): 73.2 |
|||
| 52-week | High : | 91 | Low : | 28.65 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and NEUTRAL in mid-long term.[ CORT ] has closed below upper band by 14.1%. Bollinger Bands are 40.9% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 18 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 52.53 - 52.78 | 52.78 - 53 |
| Low: | 49.72 - 50.01 | 50.01 - 50.26 |
| Close: | 51.84 - 52.3 | 52.3 - 52.69 |
Corcept Therapeutics Incorporated discovers, develops, and commercializes drugs for the treatment of severe metabolic, oncologic, and neuropsychiatric disorders in the United States. The company offers Korlym (mifepristone) tablets as a once-daily oral medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing's syndrome, who have type 2 diabetes mellitus or glucose intolerance, and have failed surgery or are not candidates for surgery. It is developing relacorilant to treat patients with Cushing's syndrome; and nab-paclitaxel in combination with relacorilant, which has completed Phase II clinical trial to treat patients with advanced ovarian tumors, as well as for the treatment of cortisol excess. The company is also developing selective cortisol modulator to treat patients with metastatic castration-resistant prostate cancer; selective cortisol modulator for the treatment of antipsychotic-induced weight gain and other disorders; and FKBP5 gene expression assays. Corcept Therapeutics Incorporated was incorporated in 1998 and is headquartered in Menlo Park, California.
Fri, 08 May 2026
Corcept Therapeutics (CORT) Is Up 11.9% After Raising 2026 Guidance On Early Lifyorli Uptake - Sahm
Thu, 07 May 2026
Corcept (CORT) CDO sells 20K shares under 10b5-1 plan - Stock Titan
Thu, 07 May 2026
Corcept Therapeutics (CORT) Is Up 11.9% After Q1 Loss, Higher 2026 Outlook And ALS Data - Has The Bull Case Changed? - Yahoo Finance
Wed, 06 May 2026
Corcept Therapeutics Incorporated - Common Stock (NQ: CORT - FinancialContent
Tue, 05 May 2026
Corcept (NASDAQ: CORT) CEO sells 40K shares under 10b5-1 plan - Stock Titan
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Outperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Neutral |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 107 (M) |
| Shares Float | 89 (M) |
| Held by Insiders | 11.5 (%) |
| Held by Institutions | 71.2 (%) |
| Shares Short | 11,340 (K) |
| Shares Short P.Month | 13,030 (K) |
| EPS | 0.34 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 6.11 |
| Profit Margin | 6.1 % |
| Operating Margin | -30.1 % |
| Return on Assets (ttm) | -0.7 % |
| Return on Equity (ttm) | 7.1 % |
| Qtrly Rev. Growth | 4.9 % |
| Gross Profit (p.s.) | 7.03 |
| Sales Per Share | 7.16 |
| EBITDA (p.s.) | -0.07 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | 120 (M) |
| Levered Free Cash Flow | 114 (M) |
| PE Ratio | 149.37 |
| PEG Ratio | 0.8 |
| Price to Book value | 8.55 |
| Price to Sales | 7.29 |
| Price to Cash Flow | 46.59 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|